Literature DB >> 10468702

Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy.

S P Wilkinson1, L Biddlestone, S Gore, N A Shepherd.   

Abstract

BACKGROUND: We have previously reported the effect of 2 years of omeprazole 40 mg daily on columnar-lined (Barrett's) oesophagus (CLO). AIMS: In the present study, follow-up has been extended to 5 years to assess the macroscopic and microscopic effects of continuing therapy. PATIENTS AND METHODS: The 23 patients have been followed for up to a further 3 years. Endoscopy with multiple biopsies was performed at the end of years 3, 4 and 5.
RESULTS: Although there had been a statistically significant regression in the length of CLO after 2 years, there was no overall further measurable change after 5 years. However, one patient showed complete macroscopic and microscopic regression. The number and size of macroscopic squamous islands within the CLO continued to increase, and there was a further increase in microscopic squamous re-epithelialization of surface mucosa, gland ducts and Barrett's gland tissue. Low-grade dysplasia was found consistently in one patient in biopsies taken up to the end of year 3 but it could not be detected thereafter.
CONCLUSIONS: Omeprazole 40 mg daily appears to have beneficial effects on CLO, although it rarely induces a complete regression. Whether the benefits will reduce the risk of malignant transformation is unknown.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468702     DOI: 10.1046/j.1365-2036.1999.00593.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  12 in total

1.  Barrett's oesophagus and proton pump inhibitors: a pathological perspective.

Authors:  N A Shepherd
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

Review 2.  Barrett's oesophagus: the new endoscopic modalities have a future.

Authors:  J Deviere
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Surveillance in Barrett's esophagus: an audit of practice.

Authors:  Adewale Ajumobi; Khaled Bahjri; Christian Jackson; Ronald Griffin
Journal:  Dig Dis Sci       Date:  2009-08-11       Impact factor: 3.199

Review 4.  Barrett oesophagus: lessons on its origins from the lesion itself.

Authors:  Stuart A C McDonald; Danielle Lavery; Nicholas A Wright; Marnix Jansen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-04       Impact factor: 46.802

5.  Proliferative activity in Barrett's esophagus before and after antireflux surgery.

Authors:  L Q Chen; C Y Hu; L Gaboury; M Pera; P Ferraro; A C Duranceau
Journal:  Ann Surg       Date:  2001-08       Impact factor: 12.969

Review 6.  The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review.

Authors:  Eugene Y Chang; Cynthia D Morris; Ann K Seltman; Robert W O'Rourke; Benjamin K Chan; John G Hunter; Blair A Jobe
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

7.  Barrett's esophagus in Japanese patients: its prevalence, form, and elongation.

Authors:  Koichi Okita; Yuji Amano; Yoshiko Takahashi; Yuko Mishima; Nobuyuki Moriyama; Norihisa Ishimura; Shunji Ishihara; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2008-12-24       Impact factor: 7.527

8.  Barrett esophagus: perspectives on its diagnosis and management in asian populations.

Authors:  Yuji Amano; Yoshikazu Kinoshita
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-01

Review 9.  Management strategies of Barrett's esophagus.

Authors:  Giovanni D De Palma
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

10.  Optimal management of Barrett's esophagus: pharmacologic, endoscopic, and surgical interventions.

Authors:  Vani Ja Konda; Kunal Dalal
Journal:  Ther Clin Risk Manag       Date:  2011-11-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.